467 related articles for article (PubMed ID: 26321082)
1. Novel mechanisms and approaches in immunotherapy for brain tumors.
Finocchiaro G; Pellegatta S
Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
3. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
4. Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.
Müller I; Altherr D; Eyrich M; Flesch B; Friedmann KS; Ketter R; Oertel J; Schwarz EC; Technau A; Urbschat S; Eichler H
Cytotherapy; 2016 Sep; 18(9):1146-61. PubMed ID: 27424145
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
6. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
Ren PP; Li M; Li TF; Han SY
Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
[TBL] [Abstract][Full Text] [Related]
7. Immune and viral therapies for malignant primary brain tumors.
Gardeck AM; Sheehan J; Low WC
Expert Opin Biol Ther; 2017 Apr; 17(4):457-474. PubMed ID: 28274139
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
Belmans J; Van Woensel M; Creyns B; Dejaegher J; Bullens DM; Van Gool SW
Sci Rep; 2017 Oct; 7(1):13902. PubMed ID: 29066810
[TBL] [Abstract][Full Text] [Related]
9. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Batich KA; Swartz AM; Sampson JH
Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
[TBL] [Abstract][Full Text] [Related]
10. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.
Samaha H; El Naggar S; Ahmed N
Immunotherapy; 2015; 7(5):481-5. PubMed ID: 26065474
[No Abstract] [Full Text] [Related]
11. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
[TBL] [Abstract][Full Text] [Related]
12. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
[TBL] [Abstract][Full Text] [Related]
13. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
16. T cell adoptive immunotherapy of newly diagnosed gliomas.
Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
[TBL] [Abstract][Full Text] [Related]
18. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
Chistiakov DA; Chekhonin IV; Chekhonin VP
Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
[TBL] [Abstract][Full Text] [Related]
19. Gammadelta T cells as immune effectors against high-grade gliomas.
Lamb LS
Immunol Res; 2009; 45(1):85-95. PubMed ID: 19711198
[TBL] [Abstract][Full Text] [Related]
20. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.
Liu K; Liu X; Peng Z; Sun H; Zhang M; Zhang J; Liu S; Hao L; Lu G; Zheng K; Gong X; Wu D; Wang F; Shen L
Oncotarget; 2015 Sep; 6(27):23735-47. PubMed ID: 26124178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]